Equities

Jiangsu Aidea Pharmaceutical Co Ltd

688488:SHH

Jiangsu Aidea Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)6.67
  • Today's Change-0.28 / -4.03%
  • Shares traded7.40m
  • 1 Year change-40.18%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments438475589
Total Receivables, Net21714697
Total Inventory185156114
Prepaid expenses29139.48
Other current assets, total3.551117
Total current assets872802827
Property, plant & equipment, net445449330
Goodwill, net131313
Intangibles, net191181165
Long term investments15114958
Note receivable - long term--1.134.23
Other long term assets------
Total assets1,7471,6551,435
LIABILITIES
Accounts payable11010949
Accrued expenses192214
Notes payable/short-term debt26215716
Current portion long-term debt/capital leases842.124.23
Other current liabilities, total17418.95
Total current liabilities49233293
Total long term debt73611.36
Total debt41822122
Deferred income tax6.286.685.86
Minority interest------
Other liabilities, total505625
Total liabilities621456125
SHAREHOLDERS EQUITY
Common stock421420420
Additional paid-in capital888886874
Retained earnings (accumulated deficit)(184)(108)16
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.550.85(0.1)
Total equity1,1261,1991,310
Total liabilities & shareholders' equity1,7471,6551,435
Total common shares outstanding421420420
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.